Cellyan Biotechnology Co., Ltd (HKPD)

Cellyan Biotechnology Balance Sheet

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023
Cash & Equivalents	0.75	0.63	0.52
Short-Term Investments	2.26	-	-
Cash & Short-Term Investments	3.01	0.63	0.52
Cash Growth	379.22%	19.57%	-
Accounts Receivable	4.66	3.7	1.65
Other Receivables	0.51	1.28	0.39
Total Trade Receivables	5.16	4.98	2.03
Inventory	0.56	0.93	0.19
Other Current Assets	-	1.26	-
Total Current Assets	8.73	7.8	2.75
Net Property, Plant & Equipment	0.59	0.83	0.65
Other Intangible Assets	0.1	0.03	0
Total Assets	9.42	8.67	3.41
Accounts Payable	1.82	1.42	1.55
Short-Term Debt	-	0.03	-
Current Portion of Long-Term Debt	0.37	0.18	0.06
Current Portion of Leases	0.49	0.63	0.36
Unearned Revenue	0.12	0.19	0.27
Other Current Liabilities	0.11	0.72	0.31
Total Current Liabilities	2.92	3.18	2.55
Long-Term Debt	1.5	1.12	0.12
Long-Term Leases	0.01	0.12	0.15
Total Long-Term Liabilities	1.51	1.24	0.27
Total Liabilities	4.43	4.41	2.82
Common Stock	0.01	0.01	0.01
Additional Paid-in Capital	3.46	3.02	0.39
Accumulated Other Comprehensive Income	0.01	-0.3	-0.01
Retained Earnings	1.5	1.53	0.2
Shareholders' Equity	4.99	4.25	0.59
Total Liabilities & Equity	9.42	8.67	3.41
Total Debt	2.37	2.09	0.69
Net Cash (Debt)	0.63	-1.46	-0.17
Net Cash Per Share	0.06	-0.17	-0.02
Book Value	4.99	4.25	0.59
Book Value Per Share	0.48	0.51	0.09
Tangible Book Value	4.89	4.22	0.58
Tangible Book Value Per Share	0.47	0.50	0.08

Updated Mar 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q